Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab combination trial in B-cell non-Hodgkin lymphoma
NL-OMON59292Phase 2Active, not recruiting
- Sponsor
- Genmab
- Start
- Oct 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of epcoritamab in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (10 arms), sponsored by Genmab. Primary endpoints: Incidence of dose-limiting toxicities, Incidence and severity of adverse events and 3 more. Started Oct 2020; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NL-OMON59292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59292.